By Fineline Cube 
Walvax Biotechnology Co., Ltd. and Pharmaniaga Lifescience Sdn. Bhd. (wholly‑owned by Pharmaniaga Berhad) today announced a joint agreement to manufacture, commercialize, and distribute the 13‑valent Pneumococcal Conjugate Vaccine (PCV‑13) in Malaysia. The partnership will transfer Walvax’s manufacturing technology to Pharmaniaga, enabling a local supply chain for the vaccine that protects infants and young children against invasive pneumococcal disease.
Collaboration Highlights
| Element | Detail |
|---|---|
| Technology Transfer | Walvax will provide production protocols, quality systems, and regulatory expertise for PCV‑13. |
| Manufacturing Hub | Pharmaniaga Lifescience will operate a dedicated facility in Malaysia, meeting WHO and national standards. |
| Commercialization Strategy | Joint marketing, pricing, and distribution plan targeting public‑sector immunization programs and private healthcare providers. |
| Regulatory Pathway | Coordinated submission to Malaysia’s Ministry of Health for local approval and registration. |
Why PCV‑13 Matters
- High‑Burden Disease – Pneumococcal infections cause >500,000 pneumonia‑related deaths worldwide each year, with infants the most vulnerable group.
- Drug‑Resistant Strains – The vaccine targets 13 serotypes, including multiple drug‑resistant clones that are rising in Asia.
- Public‑Health Impact – Introduction of PCV‑13 can reduce national childhood morbidity and mortality while lowering healthcare costs.
Forward‑Looking Statements
This release contains forward‑looking statements that are subject to risks and uncertainties. Actual results may differ materially from those expressed or implied herein.-Fineline Info & Tech